Free Trial
NASDAQ:BCAX

Bicara Therapeutics Q2 2025 Earnings Report

Bicara Therapeutics logo
$10.20 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$10.18 -0.02 (-0.20%)
As of 05:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bicara Therapeutics EPS Results

Actual EPS
N/A
Consensus EPS
-$0.54
Beat/Miss
N/A
One Year Ago EPS
N/A

Bicara Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Bicara Therapeutics Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Tuesday, August 12, 2025
Conference Call Time
7:30AM ET

Conference Call Resources

Bicara Therapeutics Earnings Headlines

REVEALED FREE: Our top 3 stocks to own in 2025 and beyond
Every time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (including the losers!).
BCAX Bicara Therapeutics Inc.
See More Bicara Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bicara Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bicara Therapeutics and other key companies, straight to your email.

About Bicara Therapeutics

Bicara Therapeutics (NASDAQ:BCAX), a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

View Bicara Therapeutics Profile

More Earnings Resources from MarketBeat